Recommended regular domestic purchasing channels for Enasidenib

Enasidenib is an oral small molecule targeted drug that is an IDH2 inhibitor. As an innovative targeted therapy drug, it is mainly used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 gene mutations. Acute myeloid leukemia is a type of highly heterogeneous and aggressive hematological malignancy. In addition to traditional chemotherapy and hematopoietic stem cell transplantation, the emergence of molecular targeted drugs provides a new option for precise treatment.

Overseas, ensidipine has been approved for marketing by the U.S.FDA and the European Medicines Agency (EMA) and has entered clinical use. As an oral targeted drug, its administration method is relatively convenient and patient compliance is high. In addition to AML, some academic research is also exploring its potential application in blood diseases such as myelodysplastic syndrome (MDS), but these uses have not yet been officially approved.

In China, ensidipine has not yet completed the official marketing process, so domestic hospital pharmacies are temporarily unable to directly provide the original drug. For patients with clinical needs, there are two main common legal ways to obtain it: first, through temporary import or clinical trial projects of the National Medical Products Administration, which usually requires a doctor to issue a condition description and apply; second, to obtain overseas approved original drugs through regular international pharmacies or cross-border medical channels, provided that a qualified institution is selected to avoid counterfeit or smuggled drugs from unknown sources.

At present, some generic drugs of encidipine are also produced and sold on the market. The active ingredients of generic drugs are basically the same as the original drugs, but there may be differences in production specifications, dosage forms and prices. For patients with a heavy financial burden, generic drugs provide an alternative, but the source must be confirmed to be regular and meet international quality standards.

Reference materials:https://www.idhifa.com/